Teva, AbbVie Face Certified Class Over Niaspan Pay-For-Delay

By Mike LaSusa (August 14, 2019, 9:41 PM EDT) -- A group of direct buyers of the cholesterol drug Niaspan scored a victory on Wednesday when a Pennsylvania federal judge approved their bid to move forward as a class with a pay-for-delay antitrust suit against Teva Pharmaceuticals Industries Ltd. and AbbVie Inc....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!